Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 11, Pages 5816-5840Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00075
Keywords
-
Categories
Funding
- GlaxoSmithKline RD, Stevenage
- University of Strathclyde
- EPSRC [EP/S035990/1]
- EPSRC [EP/S035990/1] Funding Source: UKRI
Ask authors/readers for more resources
Non-BET bromodomain-containing proteins have become attractive targets for the development of novel therapeutics targeting epigenetic pathways. To help facilitate the target validation of this class of proteins, structurally diverse small-molecule ligands and methodologies to produce selective inhibitors in a predictable fashion are in high demand. Herein, we report the development and application of atypical acetyl-lysine (KAc) methyl mimetics to take advantage of the differential stability of conserved water molecules in the bromodomain binding site. Discovery of the n-butyl group as an atypical KAc methyl mimetic allowed generation of 31 (GSK6776) as a soluble, permeable, and selective BRD7/9 inhibitor from a pyridazinone template. The nbutyl group was then used to enhance the bromodomain selectivity of an existing BRD9 inhibitor and to transform panbromodomain inhibitors into BRD7/9 selective compounds. Finally, a solvent-exposed vector was defined from the pyridazinone template to enable bifunctional molecule synthesis, and affinity enrichment chemoproteomic experiments were used to confirm several of the endogenous protein partners of BRD7 and BRD9, which form part of the chromatin remodeling PBAF and BAF complexes, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available